Clinical Trials Browser

Phase 3 × Recruiting × ibrutinib × Clear all

Hematologic Diseases, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01804686 2026-04-13

CAN3001

Phase 3 Recruiting

700 enrolled

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06136559 2026-04-13

BELLWAVE-011

Phase 3 Recruiting

1,200 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07377578 2026-02-06

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 3 Recruiting

394 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT02858258 2017-12-19

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Phase 3 Recruiting

870 enrolled

Lymphoid

Lymphoma, Mantle-Cell

Clinical Trials

BRUIN-CLL-314

CAN3001

BELLWAVE-011

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma